|Videos|February 16, 2018

The Escalating Problem & Cost of Antimicrobial Resistance

Glenn Tillotson, PhD, FIDSA, provides insight into the growing problem and cost of antimicrobial resistance.

Glenn Tillotson, PhD, FIDSA, consultant microbiologist in Durham, NC, provides insight into the growing problem and cost of antimicrobial resistance.

Interview Transcript (modified slightly for readability):

“I think antibiotic resistance, often called antimicrobial resistance, or AMR, is now recognized by the United Nations, the World Health Organization (WHO), President Obama, the Centers for Disease Control and Prevention—all of the major entities in the world recognize that AMR is a major problem. It is responsible for 23 million deaths, 2 million extra infections, and so, this is causing a major concern health wise.

The issue with AMR is that it’s like a train and it’s out of the station and is picking up speed. Unless we do something to curtail that, then we have a growing problem. There is a group in the United Kingdom led by Lord O’Neill and Lord O’Neill published a report 2 years ago that estimates that by the year 2030, we’ll be spending about $50 billion extra in health care dollars to cope with AMR. And so, it is an escalating problem. AMR is actually mentioned in the WHO’s top 5 health care crises; I think it’s in at number 3. But certainly, it’s in WHO’s top bad problems.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.